Asahi shares mark weekly slide after cyberattack halts production
Haemonetics Corp’s stock reached a new 52-week low, closing at 50.62 USD. According to InvestingPro analysis, the stock appears significantly undervalued, with a P/E ratio of 15.5x and an impressive free cash flow yield of 8%. Technical indicators from InvestingPro suggest the stock is in oversold territory. This milestone reflects a significant downturn over the past year, with the company’s stock experiencing a 33.13% decline. The medical technology firm’s recent performance underscores challenges within its sector, as market conditions and competitive pressures weigh on its stock valuation. Despite its innovative offerings in blood management solutions, Haemonetics faces hurdles that have impacted investor confidence, contributing to this notable decrease in stock price over the last year. Discover more detailed insights and 8 additional ProTips about Haemonetics in the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Haemonetics reported its fiscal first-quarter results, posting earnings per share of $1.10, which exceeded expectations by $0.09. The company’s revenue reached $321 million, surpassing forecasts by $18.38 million, with significant contributions from its Plasma and Blood Center segments. Despite these strong financial results, several analyst firms have adjusted their outlooks for Haemonetics. Mizuho lowered its price target for the company to $70, citing a slowdown in the VASCADE MVP segment, although they maintained an Outperform rating. Raymond James downgraded Haemonetics from Strong Buy to Outperform and reduced their price target to $78, highlighting a decline in the interventional technologies franchise. JPMorgan also downgraded the stock from Overweight to Neutral, setting a new price target of $62 due to mixed performance results. Additionally, Needham adjusted its price target to $68 while maintaining a Buy rating, noting increased competition. These developments reflect a cautious stance from analysts despite Haemonetics’ recent earnings beat.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.